Skip to main content

Table 1 Effects of metformin and atorvastatin on laboratory parameters

From: Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia

Variables

Sham

Control

Atorvastatin

Metformin

Combined

Initially

     

TG (mmol/L)

0.97 ± 0.10

0.96 ± 0.12

0.95 ± 0.12

0.96 ± 0.11

0.94 ± 0.12

TC (mmol/L)

3.12 ± 0.28

3.15 ± 0.30

3.18 ± 0.32

3.16 ± 0.32

3.19 ± 0.29

LDL-C (mmol/L)

1.97 ± 0.20

1.98 ± 0.20

1.99 ± 0.22

1.96 ± 0.18

2.00 ± 0.18

HDL-C (mmol/L)

1.05 ± 0.05

1.07 ± 0.04

1.06 ± 0.04

1.06 ± 0.05

1.06 ± 0.05

CRP (mg/L)

1.34 ± 0.18

1.37 ± 0.15

1.36 ± 0.15

1.35 ± 0.17

1.37 ± 0.16

ALT (U/L)

26.2 ± 3.2

26.7 ± 3.1

27.2 ± 2.9

27.1 ± 2.4

26.8 ± 2.2

AST (U/L)

27.7 ± 2.6

27.9 ± 2.1

28.0 ± 2.5

28.3 ± 3.0

27.8 ± 2.0

CK (U/L)

13.3 ± 1.4

13.7 ± 1.2

14.2 ± 1.0

14.0 ± 1.2

13.5 ± 1.1

FBG (mmol/L)

4.64 ± 0.37

4.57 ± 0.32

4.68 ± 0.30

4.66 ± 0.33

4.74 ± 0.25

6 weeks later

     

TG (mmol/L)

0.99 ± 0.10*

2.18 ± 0.31

2.17 ± 0.30

2.18 ± 0.22

2.18 ± 0.21

TC (mmol/L)

3.11 ± 0.29*

5.87 ± 0.57

5.90 ± 0.60

5.93 ± 0.62

5.91 ± 0.59

LDL-C (mmol/L)

1.95 ± 0.18*

3.83 ± 0.53

3.84 ± 0.51

3.82 ± 0.50

3.79 ± 0.50

HDL-C (mmol/L)

1.08 ± 0.05

1.09 ± 0.05

1.08 ± 0.04

1.08 ± 0.04

1.09 ± 0.05

CRP (mg/L)

1.35 ± 0.12*

7.87 ± 1.02

7.90 ± 1.06

7.88 ± 1.05

7.92 ± 1.02

ALT (U/L)

28.4 ± 3.0

29.7 ± 3.1

29.7 ± 2.2

28.8 ± 1.0

28.8 ± 1.6

AST (U/L)

28.0 ± 3.1

28.5 ± 2.2

28.1 ± 2.1

28.4 ± 2.2

28.4 ± 1.6

CK (U/L)

13.9 ± 1.2

13.2 ± 1.0

14.0 ± 1.1

13.7 ± 1.2

13.3 ± 1.5

FBG (mmol/L)

4.79 ± 0.42

5.83 ± 0.38

5.86 ± 0.35

5.92 ± 0.35

5.81 ± 0.28

4 weeks of intervention

     

TG (mmol/L)

0.97 ± 0.11*

2.19 ± 0.21

1.93 ± 0.10

2.17 ± 0.18

1.93 ± 0.12

TC (mmol/L)

3.02 ± 0.22*

5.74 ± 0.36#

4.60 ± 0.38

5.79 ± 0.37

4.52 ± 0.37

LDL-C (mmol/L)

1.91 ± 0.15*

3.72 ± 0.26#

2.91 ± 0.28

3.73 ± 0.33

2.86 ± 0.16

HDL-C (mmol/L)

1.07 ± 0.04

1.08 ± 0.04

1.09 ± 0.03

1.09 ± 0.03

1.10 ± 0.04

CRP (mg/L)

1.36 ± 0.10*

7.22 ± 1.06#

5.18 ± 0.98

5.27 ± 0.78

4.53 ± 0.73&

ALT (U/L)

27.6 ± 2.1

27.9 ± 1.1

28.5 ± 2.2

28.2 ± 1.1

28.0 ± 2.1

AST (U/L)

27.9 ± 2.2

28.2 ± 2.0

28.6 ± 2.1

28.3 ± 1.8

27.9 ± 1.2

CK (U/L)

14.6 ± 1.1

13.8 ± 1.2

14.3 ± 1.2

14.2 ± 1.1

13.9 ± 1.2

FBG (mmol/L)

4.77 ± 0.46

5.71 ± 0.45

5.72 ± 0.43

4.98 ± 0.39

5.05 ± 0.45

  1. Denote: *P < 0.05 sham group versus other group, #P < 0.05 control group versus atorvastatin and combined groups, &P < 0.05 combined group versus atorvastatin and metformin groups.